Role of Fibroblast Growth Factor 19 in Maintaining Nutrient Homeostasis and Disease

Fibroblast growth factor 19 （FGF19） is a kind of gut-derived postprandial hormone. As an atypical member of the FGF family, FGF19 functions as an endocrine hormone except regulating cell growth and differentiation. FGF19 plays a key role in coordination of liver bile acid biosynthesis and gallbladder motility, and acts as a regulator of metabolic homeostasis, including strengthening insulin sensitivity, decreasing triglyceride concentration and reducing body weight.

非小细胞肺癌组织中FGF9、SMAD2表达与临床病理特征及预后的关系

目的 分析非小细胞肺癌(NSCLC)患者癌组织中成纤维细胞生长因子9(FGF9)、SMAD2表达与临床病理特征以及预后的相关性。方法 选取本院2018年1月-2020年12月收治的75例NSCLC患者作为研究对象,收集患者手术切除癌组织与癌旁组织,免疫组化法比较癌组织与癌旁组织FGF9、SMAD2蛋白表达情况,根据患者癌组织FGF9、SMAD2表达情况将患者分为FGF9阴性表达组、FGF9阳性表达组,SMAD2阴性表达组、SMAD2阳性表达组,比较组间临床病理特征差异;采用Spearman法分析FGF9与SMAD2表达相关性;构建KM曲线,分析患者FGF9、SMAD2表达与生存期的关联;通过COX法分析影响NSCLC患者预后不良的危险因素。结果 与癌旁组织相比,NSCLC组织中FGF9表达阳性率、SMAD2表达阳性率升高(P<0.05);是否发生淋巴结转移、TNM I+II期与TNM III期NSCLC患者FGF9阳性表达率比较差异有统计学意义(P<0.05);是否淋巴结转移、TNM I+II期与TNM III期、中高分化与低分化NSCLC患者SMAD2阳性表达率比较差异有统计学意义(P<0.05);NSCLC组织中蛋白FGF9、SMAD2表达呈正相关(P<0.05);随访期间FGF9阳性表达组患者累积生存率(20.8%)低于阴性表达组(77.3%),SMAD2阳性表达组患者累积生存率(25.9%)低于阴性表达组(76.5%),组间比较差异有统计学意义(P<0.05);FGF9阳性表达组患者无进展生存率(9.4%)低于阴性表达组(63.6%),SMAD2阳性表达组患者无进展生存率(15.5%)低于阴性表达组(58.8%),组间比较差异有统计学意义(P<0.05)。结论 NSCLC组织FGF9、SMAD2阳性表达升高,均与患者临床病理特征及预后相关,FGF9、SMAD2可能共同参与NSCLC的癌进展。

Expression and significance of angiostatin, vascular endothelial growth factor and matrix metalloproteinase-9 in brain tissue of diabetic rats with ischemia reperfusion

Objective: To discuss the expression and significance of angiostatin, vascular endothelial growth factor and matrix metalloproteinase-9 in the brain tissue of diabetic rats with ischemia reperfusion. Methods: A total of 60 male Wistar rats were randomly divided into the normal group, sham group, diabetic cerebral infarction group and single cerebral infarction group according to the random number table, with 15 rats in each group. The high sucrose diet and intraperitoneal injection of streptozotocin were performed for the modeling of diabetic rats, while the thread-occlusion method was employed to build the model of cerebral ischemia reperfusion. The immunohistochemical staining was performed to detect the expression of angiostatin, vascular endothelial growth factor(VEGF) and matrix metalloproteinase-9(MMP-9) in the brain tissue. Results: The expression of angiostatin after the reperfusion in the brain tissue of rats in the single cerebral infarction group and diabetic cerebral infarction group was increased 6 h after the reperfusion, reached to the peak on 1 d and then decreased gradually. The expression of angiostatin in the diabetic cerebral infarction group 6 h, 1 d, 3 d and 7 d after the reperfusion was significantly higher than that in the single cerebral infarction group(P<0.05). VEGF began to be increased 1 h after the reperfusion in the single cerebral infarction group and diabetic cerebral infarction group, reached to the peak at 6 h and then decreased gradually. The expression of VEGF in the diabetic cerebral infarction group at each time point after the reperfusion was significantly lower than that in the single cerebral infarction group(P<0.05). MMP-9 began to be be increased 1 h after the reperfusion in the single cerebral infarction group and diabetic cerebral infarction group, reached to the peak on 1 d and then decreased gradually. The expression of MMP-9 in the diabetic cerebral infarction group at each time point after the reperfusion was significantly higher than that in the single cerebral infarction group(P<0.05). Conclusions: The high glucose environment in which the diabetic cerebral infarction is occurred is to induce the formation of MMP-9 at first and then activate and increase the expression of angiostatin. Afterwards, the expression of VEGF is inhibited, resulting in the poor angiogenesis after cerebral infarction, which thus makes the injury of brain tissue after cerebral infarction even worse than the non-diabetes mellitus.

Porcine growth differentiation factor 9 gene polymorphisms and their associations with litter size

Growth differentiation factor 9 （GDF9） is expressed in oocytes and is thought to be required for ovarian folliculogenesis. Given this function, GDF9 may be considered as a candidate gene controlling pig ovulate rate. In this study, the complete coding sequence was cloned （encoding a 444 amino acid）, intron sequence and partial 5＇-UTR of pig GDF9. RT-PCR results showed that GDF9 mRNA is expressed in a wide range of tissues of the ruttish Erhualian pig. The expression levels of GDF9 mRNA in pituitary, ovary, uterus and oviduct are higher in the Erhualian pigs than those in Duroc pigs, especially in pituitary with a significant difference （P 〈 0.05）. Comparative sequencing revealed 12 polymorphisms, including 8 single nucleotide polymorphisms （SNPs） and one 314 bp indel in noncoding regions, and the other 3 SNPs in coding regions. Four polymorphisms, G359C, C1801T, T1806C and 314 bp indel, were developed as markers for further use in population variation and association studies. The G359C polymorphism segregates only in Chinese native pigs, Erhualian and Dahuabai, on the contrary, 314 bp indel segregates only in Duroc and Landrace. C1801T and T1806C sites seem to be completely linked and segregate in Erhualian, Dahuabai and Landrace. In a word, GDF9 may be not associated with pig litter size in extensive populations as per the studies of allele distributions of the four polymorphisms and pilot association in four breeds.

Matrix metalloproteinase-9 and vascular endothelial growth factor expression change in experimental retinal neovascularization

AIM： To investigate the signal transduction mechanism of matrix metalloproteinase-9 （MMP-9） mediatedvascular endothelial growth factor （VEGF） expression and retinal neovascularization （RNV） in oxygen-induced retinopathy （OIR） model. METHODS： C57BL/6J mice were divided into four groups： control group, OIR group, OIR control group （phosphatebuffered saline by intravitreal injection） and treated group [tissue inhibitor of matrix metalloproteinase-1 （TIMP-1） by intravitreal injection]. OIR model was established in C57BIJ6J mice exposed to 75% ＋2% oxygen for 5d. mRNA level and protein expression of MMP-9, TIMP-1 and VEGF were measured by real-time polymerase chain reaction and Western blotting, and located by immunohistochemistry. RESULTS： Levels of MMP-9 and VEGF in retina were significantly increased in animals with OIR and OIR control group. Levels of TIMP -1 in retina was significantly reduced in animals with OIR and OIR control group. Furthermore, a significant correlation was found between MMP-9 and VEGF. Intravitreal injection of TIMP- 1 significantly reduced MMP-9 and VEGF expression of the OIR mouse model （all P〈0.05）. CONCLUSION： These results demonstrate that MMP- 9-mediated up-regulation of VEGF promotes RNV in retinopathy of prematurity （ROP）. TIMP-1 may be a potential target for the prevention and treatment of ROP.

The ORF 113 of Heliocoverpa armigera Single Nucleopolyhedrovirus Encodes a Functional Fibroblast Growth Factor

Fibroblast growth factor (FGF) is a key regulator of developmental processes. A FGF homolog (vFGF) is found in all lepidopteran baculoviruses. Autographa californica nucleopolyhedrovirus (AcMNPV) and Bombyx mori NPV (BmNPV) vFGFs are chemotactic factors. Here we analyzed the vfgf of Helicoverpa armigera NPV (HearNPV), a group II NPV. The HearNPV vfgf transcripts were detected from 18 to 96 h post-infection (hpi) of Hz-AM1 cells with HearNPV and encoded a 36 kDa protein, which was secreted into the culture medium. HearNPV vFGF had strong affinity to heparin, a property important for FGF signaling via an FGF receptor. Unlike its AcMNPV homolog, HearNPV vFGF specially chemoattracted Hz-AM1, but not other insect cells such as Sf9 and Se-UCR and not the mammalian cells 293 and HepG2. HearNPV vFGF is also associated with the envelope of BV but is absent in occlusion-derived virus, which coordinated to the chemotatic activity analysis.

Synergistic Effects of Activin A and Fibroblast Growth Factor 2 in the Modulation of Insulin Expression

Diabetes is the most prevalent and serious metabolic disease, and the number of diabetic patients worldwide is increasing. The reduction of insulin biosynthes is in pancreatic E-cells is closely associated with the onset and progression of diabetes, therefore, it is important to search for ways to induce insulin-producing cells in non-E-cells. In the present study, it has been reported that activin A and a basic fibroblast growth factor 2 （ FGF2）, can synergistically increase the insulin mRNA level, in both mouse El4 striatal primary cell cultures and the hippocampal neuronal cell line HT22. Activin A and FGF2 can jointly stimulate the nuclear translocation of Smad3 and specifically activate ERK1/2. It is interesting to note that a specific inhibitor for MEK, U0126, can efficiently block the induction of an insulin promoter activity by activin A and FGF2. This indicates that activin A collaborates with FGF2, giving a signal to induce the insulin gene through selective activation of the ERK-type MAP kinase and Smad3 in mouse striatal and HT22 cells. These data suggest that activin A may act in concert with FGF2 for the development of insulin -positive neurons

血清sCD164、FGF9水平对晚期非小细胞肺癌患者化疗疗效及预后的评估价值

目的 探究血清可溶性CD164(sCD164)、成纤维细胞生长因子9 (FGF9)水平与晚期非小细胞肺癌(NSCLC)患者化疗疗效的关系及预后评估的价值。方法 选取2020年1月至2022年12月该院诊治的121例晚期NSCLC患者(NSCLC组)和70例同期进行体检的健康者(对照组)。采用酶联免疫吸附试验检测各组血清sCD164、FGF9水平。采用受试者工作特征曲线分析血清sCD164、FGF9对晚期NSCLC患者化疗疗效的预测价值。采用Kaplan-Meier曲线和多因素COX回归分析血清sCD164、FGF9水平与晚期NSCLC患者预后的关系。结果 NSCLC组血清sCD164、FGF9水平高于对照组(均P<0.05)。TNM分期Ⅳ期、低分化NSCLC患者血清sCD164、FGF9水平分别高于TNM分期Ⅲb期、高中分化患者(均P<0.05)。化疗无效组血清sCD164、FGF9水平高于化疗有效组(均P<0.05)。血清sCD164、FGF9联合预测晚期NSCLC患者化疗疗效的曲线下面积为0.955,大于单项预测的0.852、0.876(均P<0.05)。sCD164高水平组、FGF9高水平组1年累积生存率分别低于sCD164低水平组、FGF9低水平组(均P<0.05)。TNM分期Ⅳ期、低分化程度、sCD164高水平、FGF9高水平是影响晚期NSCLC患者预后的危险因素(均P<0.05)。结论 晚期NSCLC患者血清sCD164、FGF9水平升高,二者与肿瘤TNM分期、分化程度及化疗疗效有关,是影响晚期NSCLC患者预后的独立危险因素。

Contrary Regulation of TIMP-1 and MMP-9 by Hepatocyte Growth Factor Antibody after Lung Injury

Objective To study the influence of hepatocyte growth factor (HGF) antibody on the lung expression level of matrix metalloproteinases-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1). Methods Thirty male Wistar rats were randomly divided into 3 groups: control group, model group, and intervention group. Endotoxin was intratracheally infused in the model and intervention groups. HGF antibody was injected in the rats of the intervention group from day 1 to day 14, while the same volume of saline was injected in the control group. The rats were sacrificed on day 28 after endotoxin treatment. The amounts of MMP-9 mRNA and TIMP-1 mRNA were measured by reverse transcription-polymerase chain reaction, and protein expression levels of MMP-9 and TIMP-1 were measured by immunohistochemistry. Results In the model group, both mRNA and protein expression levels of TIMP-1 were significantly increased, the same as MMP-9. In the intervention group, the increase of TIMP-1 was remarkably reduced compared with the model group, while the mRNA and protein expression levels of MMP-9 were still increased. Conclusion HGF activity may accelerate the repair of lung injury through contrary regulating the expression levels of TIMP-1 and MMP-9.

青藤碱通过miR-23b-3p/FGF9诱导人类风湿关节炎成纤维细胞样滑膜细胞凋亡

目的:研究青藤碱(SIN)对人类风湿关节炎(RA)成纤维细胞样滑膜细胞(FLS)凋亡的影响及分子机制。方法:分离培养人RA FLS,用100 mg/L的脂多糖(LPS)处理记为LPS组;3.2 mmol/L SIN和100 mg/L LPS共同处理细胞,记为LPS+SIN组;不作任何处理的细胞作为空白(blank)组。将miR-con、miR-23b-3p、si-con和si-成纤维细胞生长因子9(FGF9)转染至RA FLS中再用100 mg/L LPS处理,分别记为LPS+miR-con组、LPS+miR-23b-3p组、LPS+si-con组和LPS+si-FGF9组;将anti-miR-con、anti-miR-23b-3p、pcDNA和pcDNA-FGF9转染至RA FLS中,再用3.2 mmol/L SIN和100 mg/L LPS共同处理,分别记为LPS+SIN+anti-miR-con组、LPS+SIN+anti-miR-23b-3p组、LPS+SIN+pcDNA组和LPS+SIN+pcDNA-FGF9组。CCK-8法检测细胞活力;集落形成实验检测细胞的集落形成数;West⁃ern blot法检测FGF9、cleaved caspase-3、Bax和Bcl-2蛋白水平;流式细胞术检测细胞凋亡;RT-qPCR检测miR-23b-3p和FGF9 mRNA的表达水平;双萤光素酶报告基因实验验证miR-23b-3p和FGF9的靶向关系。结果:SIN促进LPS诱导的RA FLS凋亡,抑制细胞增殖,上调miR-23b-3p表达,下调FGF9表达。miR-23b-3p靶向调控FGF9,过表达miR-23b-3p或沉默FGF9抑制LPS诱导的RA FLS增殖并促进细胞凋亡。干扰miR-23b-3p或过表达FGF9逆转了SIN对LPS诱导的RA FLS增殖和凋亡的影响。结论:青藤碱可通过miR-23b-3p/FGF9轴诱导RA FLS凋亡,抑制细胞增殖。

miR-323通过FGF9调控缺氧诱导的心肌H9C2细胞凋亡

目的:探讨微小RNA-323(miR-323)对缺氧诱导大鼠心肌H9C2细胞凋亡的影响及其机制。方法:建立缺氧损伤的H9C2细胞模型,在H9C2细胞转染anti-miR-323、pcDNA-FGF9和si-FGF9,并缺氧处理48 h。采用qPCR检测miR-323的表达,Western blot检测成纤维细胞生长因子9(FGF9)、cleaved caspase-3、c-Jun氨基末端激酶(JNK)和p-JNK的蛋白水平,MTT比色法检测细胞活力,流式细胞术检测细胞凋亡。生物学信息预测miR-323的靶基因并用双萤光素酶报告基因进一步验证。结果:缺氧明显降低H9C2细胞12 h、24 h和48 h的细胞活力(P<0.05),显著提高细胞凋亡率和cleaved caspase-3的蛋白水平(P<0.05),效应均呈时间依赖性。缺氧处理的H9C2细胞中miR-323和p-JNK水平上调,FGF9蛋白表达下调(P<0.05)。下调miR-323表达或过表达FGF9显著提高缺氧处理的H9C2细胞活力,降低细胞凋亡率和cleaved caspase-3蛋白的水平(P<0.05)。FGF9是miR-323的靶基因。下调FGF9表达逆转下调miR-323表达对缺氧诱导H9C2细胞损伤的抑制作用。miR-323调控FGF9影响p-JNK水平。结论:miR-323通过靶向FGF9调节JNK信号通路,从而影响缺氧处理心肌H9C2细胞的活力和凋亡。

miR-9-5p靶向FGF9抑制胃癌细胞迁移侵袭的作用机制

目的:探讨miR-9-5p在胃癌组织中的表达及对胃癌细胞株SGC7901、AGS细胞迁移和侵袭影响的作用机制。方法:real-time PCR和Western blot检测癌旁组织、胃癌组织及其细胞系中miR-9-5p和FGF9的表达;Transwell小室检测过表达miR-9-5p或敲除FGF9对SGC7901和AGS细胞迁移和侵袭能力的影响;TargetScan在线分析、双荧光素酶报告基因和Western blot实验验证miR-9-5p和FGF9的靶向关系;将转染后的SGC7901细胞分为对照(NC)组和实验(miR-9-5p)组接种于裸鼠右侧腋窝皮下,观察记录裸鼠成瘤情况并绘制生长曲线。结果:与癌旁组织相比,胃癌组织及其细胞系中miR-9-5p表达下调、FGF9表达上调(P<0.05);过表达miR-9-5p或敲除FGF9能抑制SGC7901、AGS细胞迁移和侵袭;TargetScan在线分析、双荧光素酶报告基因和Western blot实验表明miR-9-5p能调控FGF9表达;miR-9-5p组细胞成瘤速度较NC组慢(P<0.05),肿瘤体积及重量小(P<0.05)。结论:miR-9-5p在胃癌组织中表达下调,过表达miR-9-5p可抑制FGF9表达,从而抑制胃癌细胞的迁移和侵袭,减缓肿瘤生长。

miRNA-182通过FGF9调节肺动脉平滑肌细胞表型的研究

目的研究miRNA-182及其靶蛋白成纤维生长因子9(FGF9)对肺动脉平滑肌细胞表型转换的调节作用。方法体外培养大鼠肺动脉平滑肌细胞(PASMC),用miRNA-182模拟体转染的方法使其过表达,FGF9siRNA转染使其沉默;使用CCK8方法检测细胞增殖能力,分别用RT-q PCR检测miRNA-182的表达,PCR方法检测FGF9及收缩型表型标记物(SMA,SM22α及myosin)的基因水平,Western blot检测其蛋白水平。结果过表达miRNA-182,收缩表型标记物SMA,SM22α及myosin基因表达水平明显升高,SMA蛋白表达量明显增加,转染miRNA-182抑制物之后,SMA蛋白表达量降低;另外,细胞相对吸光度降低,增殖被抑制,并且转染模拟体80 nmol/L较转染40 nmol/L吸光度更低;而转染miRNA-182抑制物之后,细胞相对吸光度明显增强,细胞增殖增加。过表达miR-182后,FGF9mRNA的表达明显降低,并且与模拟体的转染浓度直接相关。沉默FGF9表达之后SMA、SM22α和myosin表达增加,并抑制PASMC的增殖能力,同时沉默miR-182和FGF9表达之后,SMA、SM22α和myosin表达增高。结论miRNA-182通过靶向抑制FGF9蛋白的表达,抑制PASMC收缩型向合成型转化,同时抑制其增殖能力。

血清微小RNA-499a-5p、成纤维细胞生长因子9、炎性因子与脓毒症所致急性肺损伤患者病情严重程度和预后的关系

目的探讨血清微小RNA-499a-5p(miR-499a-5p)、成纤维细胞生长因子9(FGF9)、炎性因子与脓毒症所致急性肺损伤(ALI)患者病情严重程度和预后的关系。方法选取接受诊治的151例脓毒症患者为研究对象,根据ALI的发生情况分为脓毒症并发ALI组(68例)和一般脓毒症组(83例)。根据氧合指数,将脓毒症并发ALI患者分为轻症组(23例)、中症组(26例)和重症组(19例)。以脓毒症并发ALI患者诊治28 d内的生存情况,分为预后良好组(43例)和预后不良组(25例)。另外,选取同期体检健康者151例为健康组。分析各组miR-499a-5p、FGF9及炎症因子间的差异和相关性。采用受试者工作特征(ROC)曲线分析血清miR-499a-5p、FGF9对脓毒症患者并发ALI的预测效能。结果轻症组、中症组、重症组患者的miR-499a-5p和FGF9水平表现为依次降低,而炎症因子白细胞介素-1(IL-1)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)水平依次升高,差异有统计学意义(P<0.05)。预后不良组的miR-499a-5p、FGF9低于预后良好组,IL-1、IL-6、TNF-α、CRP水平高于预后良好组,差异有统计学意义(P<0.05)。脓毒症并发ALI患者的miR-499a-5p、FGF9与IL-1、IL-6、TNF-α、CRP呈负相关(P<0.05);miR-499a-5p可正向调节FGF9表达(P<0.05)。miR-93、miR-135a联合预测脓毒症并发ALI患者预后的诊断效能高于单独预测,差异有统计学意义(P<0.05)。结论miR-499a-5p、FGF9、炎性因子水平与脓毒症所致ALI患者的病情程度和预后相关。miR-499a-5p和FGF9可能作为潜在的生物标志物用于脓毒症并发ALI的预后评估。

小鼠FGF9在大肠杆菌中的表达与纯化

为了建立小鼠FGF9的原核表达体系,获得纯化的FGF9重组蛋白,采用PCR技术扩增FGF9,并将其克隆入原核表达载体pET30a(+)中,经测序验证后将该重组质粒转入大肠杆菌BL21(DE3)中进行表达,采用亲和层析技术进行目的蛋白的纯化,并用Western blotting进行了免疫原性验证。测序结果显示插入到载体中的片段与FGF9的天然序列一致,在BL21(DE3)中表达出了可溶性的FGF9重组蛋白,其表达量达到总蛋白的40%;用镍螯合亲和层析方法获得了纯度大于95%的FGF9重组蛋白。

3D打印技术用于经鼻蝶窦入路垂体腺瘤切除术应用效果及对血清MMP-9和IGF-1水平的影响

目的:探究3D打印技术在经鼻蝶窦入路垂体腺瘤(PA)切除术的应用效果及对血清基质金属蛋白酶-9(MMP-9)和胰岛素样生长因子-1(IGF-1)水平的影响。方法:选取2020年5月至2022年5月秦皇岛市第一医院收治的84例PA患者,按照随机数表法将其分为观察组和对照组,每组42例。对照组行经鼻蝶窦入路垂体腺瘤切除术,观察组行经鼻蝶窦入路垂体腺瘤切除术联合应用3D打印技术,比较两组肿瘤切除效果、围术期指标、视力改善情况、MMP-9和IGF-1水平,以及鼻腔功能的鼻气道阻力(NAR)、T&T嗅觉测试评分及并发症。结果:观察组肿瘤切除效果优于对照组,差异有统计学意义(U=2.286,P<0.05);观察组手术时间、术中出血量及住院时间均少于对照组,差异有统计学意义(t=4.780、11.438、11.842,P<0.05);术后3 d、7 d时观察组血清MMP-9和IGF-1水平低于对照组,差异有统计学意义(F=7.526、4.985,P<0.05);术后1个月、3个月时观察组NAR及T&T嗅觉测试评分低于对照组,差异有统计学意义(F=6.359、8.436,P<0.05);两组视力视野改善情况及并发症发生率比较,差异无统计学意义(P>0.05)。结论:3D打印技术用于经鼻蝶窦入路垂体腺瘤切除术可提高肿瘤切除效果,优化手术操作,减少创伤,有利于减轻疼痛,改善嗅觉功能与视力视野,并能降低血清MMP-9、IGF-1水平,且安全性较高。

信迪利单抗联合贝伐珠单抗治疗不可切除肝细胞肝癌患者效果及其血清VEGF、MMP-9水平变化

目的 探讨信迪利单抗联合贝伐珠单抗治疗不可切除肝细胞肝癌患者效果及其血清血管内皮生长因子(VEGF)、基质金属蛋白酶-9(MMP-9)水平变化。方法 选取2021年1月至2022年12月在周口市中心医院确诊的80例不可切除肝细胞肝癌患者,根据患者治疗方式将患者分为单抗联合组和对照组。对照组患者接受口服甲苯磺酸索拉非尼治疗,纳入36例;单抗联合组接受信迪利单抗联合贝伐珠单抗治疗,纳入44例。记录两组患者治疗4个周期后的病情控制率和客观缓解率,比较治疗前、治疗2个周期后、治疗4个周期后血清VEGF和MMP-9水平变化,比较治疗毒副作用发生情况。随访6~30个月,绘制生存曲线,比较两组患者中位总生存时间(OS)和中位无进展生存时间(PFS)。结果 单抗联合组患者病情控制率和客观缓解率分别为77.27%和25.00%,对照组分别为44.44%和5.56%,差异有统计学意义(P<0.05)。治疗后,单抗联合组患者血清VEGF和MMP-9水平均随着时间降低,且低于对照组,差异有统计学意义(P<0.05)。单抗联合组患者甲状腺功能减退发生率为18.18%,对照组为2.78%,差异有统计学意义(P<0.05);单抗联合组患者脱发和手足综合征发生率均为0,对照组分别为22.22%和27.78%,差异均有统计学意义(P<0.05)。所有患者中位随访时间为18个月,单抗联合组患者中位OS和中位PFS分别为16.9个月和4.8个月,对照组患者中位OS和中位PFS分别为10.5个月和3个月,两组比较差异有统计学意义(P<0.05)。结论 信迪利单抗联合贝伐珠单抗治疗可以较好地控制不可切除肝细胞肝癌患者病情发展,显著降低血清肿瘤相关因子水平,提高生存率,且安全性较好。

scAAV9-IGF-1对SOD1-G93A小鼠抗凋亡通路的作用

目的 探索以自我互补双链腺相关病毒9为载体介导的人胰岛素样生长因子-1 (scAAV9-IGF-1)对SOD1-G93A转基因小鼠抗凋亡通路的作用。方法 采用肌萎缩侧索硬化(ALS)的动物模型即转基因SOD1-G93A突变型及野生型(wild type-SOD1,WT-SOD1)小鼠,在其出生后60 d龄时,雌性同窝阳性SOD1-G93A转基因小鼠采用随机的方法分配到治疗组及溶剂对照组,治疗组全身多点肌肉注射scAAV9-IGF-1,溶剂对照组多点肌肉注射AAV9-GFP,同年龄WT-SOD1作为阴性对照组。在肌肉注射40~50 d后,利用PCR技术检测腰髓中IGF-1含量的变化,同时检测抗凋亡通路因子Bcl-xl、Bcl-2的mRNA含量变化,通过免疫组化染色观察抗凋亡通路因子Bcl-xl、Bcl-2在小鼠腰髓前角神经元中的表达。结果 PCR技术检测显示scAAV9-IGF-1处理后,腰髓中IGF-1的mRNA含量显著高于GFP对照组,抗凋亡通路因子Bclxl、Bcl-2的mRNA含量均高于溶剂对照组(均P<0.05),而与WT组差异无统计学意义。免疫组化染色结果显示,治疗组中抗凋亡通路蛋白Bcl-xl,Bcl-2在小鼠腰髓前角神经元中的表达多于溶剂对照组,并且与WT阴性对照组相当。结论 scAAV9-IGF-1可以激活SOD1-G93A转基因小鼠模型中的抗凋亡通路,其通过上调Bcl-xl,Bcl-2的mRNA水平,进而增加Bcl-xl、Bcl-2的蛋白表达,从而产生抗凋亡的作用。

肝细胞癌患者血清ECM1、MMP-9和VEGF水平的变化及其意义

目的 探究肝细胞癌患者血清细胞外基质蛋白-1(ECM1)、基质金属蛋白酶-9(MMP-9和血管内皮生长因子(VEGF)水平的变化及其意义。方法 对60例肝细胞癌患者进行回顾性分析,患者主要使用甲磺酸阿帕替尼进行治疗,必要时也可联合GEMOX方案肝动脉化疗栓塞术进行治疗。采用酶联免疫吸附法测定患者治疗前后的血清ECM1、VEGF、MMP-9水平。比较患者治疗前后ECM1、MMP-9和VEGF水平;比较不同临床病理特征(年龄、性别、血管侵犯、淋巴结转移、TNM分期、Edmondson分期和肿瘤直径)患者ECM1、MMP-9和VEGF水平。结果 治疗后,患者ECM1、MMP-9以及VEGF水平分别为(135.23±44.58)pg/ml、(421.25±87.56)μg/L和(657.56±54.56)pg/ml,均低于治疗前的(215.56±30.80)pg/ml、(499.56±30.56)μg/L、(798.02±50.79)pg/ml(P<0.05)。不同年龄、性别患者ECM1、MMP-9、VEGF水平比较差异无统计学意义(P>0.05);不同血管侵犯、淋巴结转移、TNM分期、Edmondson分期和肿瘤直径患者ECM1、MMP-9、VEGF水平比较差异具有统计学意义(P<0.05)。结论 ECM1、MMP-9、VEGF三者相互作用可促进肝癌细胞的转移,可根据其水平情况,了解患者肝细胞、肝功能健康状况。

仿生电刺激联合人工周期对卵巢储备功能减退患者子宫容受性及血清生长分化因子-9、抑制素B、骨形态发生蛋白-10水平的影响

目的探讨仿生电刺激联合人工周期对卵巢储备功能减退(DOR)患者子宫容受性及血清生长分化因子-9(GDF-9)、抑制素B(INHB)、骨形态发生蛋白-10(BMP-10)水平的影响。方法选取2019年1月至2022年3月广西壮族自治区妇幼保健院收治的87例DOR患者作为研究对象。采用随机数字表法分为A组、B组、C组,每组29例。A组采用仿生电刺激治疗,B组采用人工周期治疗,C组采用仿生电刺激联合人工周期治疗。比较三组治疗前后子宫容受性,血清GDF-9、INHB、BMP-10水平,子宫内膜血流参数及卵巢体积;随访1年,比较三组的妊娠情况;比较三组治疗期间不良反应发生情况。结果与治疗前比较,治疗后A组、B组、C组初级卵泡数、优势卵泡数、排卵数及血清GDF-9、INHB、BMP-10水平均升高,卵巢体积均增大,且A组、B组、C组呈增高趋势(P<0.05)。与治疗前比较,治疗后A组、B组、C组子宫内膜血流搏动指数(PI)、子宫内膜血流阻力指数(RI)均减小,且A组、B组、C组呈下降趋势(P<0.05)。随访1年,C组妊娠率高于A组、B组(P<0.05)。治疗期间,三组不良反应发生率比较,差异无统计学意义(P>0.05)。结论仿生电刺激联合人工周期可提高DOR患者子宫容受性,改善子宫内膜血流参数及卵巢体积,也可改善血清GDF-9、INHB、BMP-10水平,提高自然妊娠率,且安全性好。